netFormulary NHS
North Central London
Joint Formulary
 Search
 Formulary Chapter 5: Infections - Full Chapter
Notes:

Prescribing of systemic antimicrobials is 'protected'. All prescribing MUST be in accordance with the Trust Antimicrobial Policy and in conjunction with local antimicrobial guideline:

 Details...
05.03.04  Expand sub section  Influenza
Oseltamivir
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Indicated for the prophylaxis and treatment of influenza, as per NICE guidelines
  • RFL:
    • Virology/Microbiology/ID approval only
  • RNOH:
    • Microbiologist approval only
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NICE TA158 (amantadine NOT recommended): Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
Link  NICE TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza
   
Zanamivir inhalation
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Indicated for the prophylaxis and treatment of influenza, as per NICE guidelines
  • RFL:
    • Virology/Microbiology/ID approval only
  • RNOH:
    • Microbiologist approval only
  • UCLH:
  • WH:
    • Microbiology approval only
 
Link  NICE TA158 (amantadine NOT recommended): Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
Link  NICE TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza
   
Amantadine
(Influenza)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Virology/Microbiology/ID approval only
  • RNOH:
    • Microbiologist approval only
  • UCLH:
  • WH:
    • Microbiologist approval only
 
Link  NICE TA158 (amantadine NOT recommended): Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
Link  NICE TA168 (amantadine NOT recommended): Amantadine, oseltamivir and zanamivir for the treatment of influenza
   
Zanamivir injection
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red

Approved for for treatment of complicated and potentially life-threatening influenza A or B virus infection in patient's whose influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/or other anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient (JFC September 2019).

Provider notes

  • NMUH:
    • Microbiology approval only
  • RFL:
    • Virology/Microbiology/ID approval only
  • RNOH:
    • Requires Microbiology approval
  • UCLH:
  • WH:
    • Microbiology approval only
 
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

GP - 1st

Medicines suitable for first-line use within primary care.

Can be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies, for example the BNF, BNF for Children, Medicines for Children or Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing. 

  

GP - 2nd

Medicines suitable for second-line use within primary care.

Can be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies, for example the BNF, BNF for Children, Medicines for Children or Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing. 

  

GP - Amber

Medicines that should be initiated by a specialist. Prescribing can be transferred to primary care once the patient has been stabilised.  

Shared care: For drugs with regular, ongoing need for monitoring and/or assessment of efficacy or toxicity. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s) (DTC) and approved by the North Central London JFC.

Fact sheet: For drugs with some concerns surrounding safety or efficacy but do not require regular monitoring and/or monitoring of effectiveness/toxicity.

  

GP - Red

Medicines which should normally be prescribed by specialists only (hospital only).

For patients already receiving prescriptions in primary care - continue. No new patients to receive prescriptions in primary care.

  

GP - Grey

Medicines on hospital formularies which have not been reviewed for suitability in primary care.  

Black

Medicines not recommended for routine use in primary or secondary care.

Medicines, which the North Central London JFC has actively reviewed and does not recommend for use at present due to limited clinical and/or cost effective data.

  

netFormulary